item management s discussion and analysis of financial condition and results of operations 
management s discussion and analysis of financial condition and results of operations that follows contains forward looking statements based on current management expectations 
meaningful factors which could cause future results to differ materially from such expectations include  without limitation  the following i the results from the phase iii clinical trials for the altropane tm imaging agent  ii scientific data collected on the company s technologies currently in preclinical research and development  iii decisions made by the fda or other regulatory bodies with respect to the initiation of human clinical trials  iv decisions made by the fda or other regulatory bodies with respect to approval and to the commercial sale of any of the company s proposed products  v the commercial acceptance of any products approved for sale and the ability of the company to manufacture  distribute and sell for a profit any products approved for sale  vi the company s ability to obtain the necessary patents and proprietary rights to effectively protect its proposed products and technologies  and vii the outcome of any collaborations or alliances currently entered into by the company or to be entered into by the company in the future with pharmaceutical or other biotechnology companies 
results of operations overview we are a development stage biotechnology company engaged in the research and development of novel therapeutic and diagnostic products to treat chronic debilitating diseases such as cancer  cns disorders and autoimmune diseases 
during the period from inception through december   the company has devoted substantially all of its efforts to business planning  raising financing  furthering the research and development of its technologies  and corporate partnering efforts 
accordingly  the company is considered to be in the development stage as defined in statement of financial accounting standards no 
year ended december  and the company s net loss was  during the year ended december  as compared with  during the year ended december  net loss per common share totaled per share during as compared with per share  excluding preferred stock preferences  during the lower net loss in was primarily due to certain non recurring charges in  including the write off of previously acquired technology of  and a charge of  for purchased in process research and development 
the effect of these items were partially offset by higher clinical and pre clinical research and development expenses in the net loss available to common stockholders for the period  including preferred stock preferences of  totaled  net loss per common share available to common stockholders for the year ended december   including attributable to preferred stock preferences  totaled 
in february  the company completed a private placement of series c convertible preferred stock and warrants 
based on the market price of the company s stock on the date of issuance  the preferred stock had a beneficial conversion feature with an intrinsic value of approximately million  which is included in the preferred stock preferences 
an additional million of preferred stock preferences were recorded to accrete the series c stock to redemption value 
in addition  in november  the company extended an exchange offer to the series c stockholders wherein it agreed to issue certain consideration for each share of series c stock converted into common stock 
a charge of approximately million  representing the fair value of the consideration issued  is also included in the preferred stock preferences 
revenue was zero during the year ended december  as compared with  during the year ended december  in september  the company recognized an one time payment related to a licensing agreement with a major pharmaceutical company as further described below 
research and development expenses were  during the year ended december  as compared with  during the year ended december  the decrease in was primarily due to the write off of previously acquired technology of  in  offset by higher clinical trial expenses and increased product manufacturing costs in during  a phase ii clinical trial was initiated and the company incurred higher costs for a phase iii clinical trial that was in process during both periods 
the company also incurred higher product manufacturing costs during related to the establishment of a gmp manufacturing process for one technology and higher pre clinical manufacturing scale up costs for another technology 
general and administrative expenses were  during the year ended december  as compared with  during the year ended december  the increase in was primarily due to higher non recurring and non cash professional service costs 
purchased in process research and development expenses were zero during the year ended december  as compared with  during the year ended december  in september  the company issued common stock and warrants to obtain an option to acquire the licensing rights to certain technology as further described below 
interest income was  during the year ended december  as compared with interest income of  during the year ended december  the increase in was due to higher average cash and investment balances during interest expense totaled  in as compared to  in the decrease in was due to a lower daily average balance on the million of convertible debentures during the period 
the debentures were issued in september and were converted into common stock in february and march at december   the company had net deferred tax assets of approximately million for which a full valuation allowance has been established 
as a result of its concentrated efforts on research and development  the company has a history of incurring net operating losses and expects to incur additional net operating losses for the foreseeable future 
accordingly  management has concluded that it is more likely than not that the future benefits related to the deferred tax assets will not be realized and  therefore  provided a full valuation allowance for these assets 
in the event the company achieves profitability  these deferred tax assets may be available to offset future income tax liabilities and expense 
year ended december  and the company s net loss was  during the year ended december  as compared with  during the year ended december  net loss per common share  excluding preferred stock preferences  totaled per share during as compared with per share during the higher net loss in is primarily related to higher research and development expenses  including the write off of acquired technology of  and the purchased in process research and development charge of  the net loss available to common stockholders for the period  including preferred stock preferences of  totaled  net loss per common share available to common stockholders for the year ended december   including attributable to preferred stock preferences  totaled 
in february  the company completed a private placement of series c convertible preferred stock and warrants 
based on the market price of the company s stock on the date of issuance  the preferred stock had a beneficial conversion feature with an intrinsic value of approximately million which is included in the preferred stock preferences 
an additional million of preferred stock preferences were recorded to accrete the series c stock to redemption value 
in addition  in november  the company extended an exchange offer to the series c stockholders wherein it agreed to issue certain consideration for each share of series c stock converted into common stock 
a charge of approximately million  representing the fair value of the consideration issued  is also included in the preferred stock preferences 
revenue was  during the year ended december  as compared with zero during the year ended december  in september  the company announced that it had entered into a development and licensing agreement with a major pharmaceutical company to develop a major sector of the company s transcription factor technology 
under the terms of the agreement  the pharmaceutical company will screen its small molecule collection for potential inhibitors of the transcription factor  with the goal of developing a small molecule therapeutic drug for the treatment of a wide range of allergies and asthma 
the company will also receive royalties on eventual sales of any product derived from the development effort 
the company received a one time payment upon the execution of the development and licensing agreement  which was recognized as revenue because the company has no remaining performance obligations 
research and development expenses were  during the year ended december  as compared with  during the year ended december  the increase in principally related to the write off of acquired technology of  and the initiation and substantial completion of a patient phase iii clinical trial 
general and administrative expenses were  during the year ended december  as compared with  during the year ended december  the increase in primarily related to higher professional services costs which were partially offset by the absence of non cash charges related to certain changes in the provisions of the company s stock option plans and the issuance of warrants to a financial advisor  both of which occurred in purchased in process research and development expenses was  during the year ended december  as compared with zero during the year ended december  in september  the company finalized an agreement under which it obtained an option to acquire the licensing rights to certain technology 
the company issued  shares of common stock and  warrants exercisable to purchase the company s common stock at an exercise price of per share as consideration for the option 
the fair value of such consideration of  was recognized as purchased in process research and development expense 
interest income was  during the year ended december  as compared with interest income of  during the year ended december  average cash and investment balances during were higher in comparison to as the result of three private placements completed in which raised gross proceeds of million 
interest expense totaled  in as compared to zero in in september  the company issued million of convertible debentures  and incurred  in interest on the coupon and  in non cash interest associated with the accretion of the discounted carrying value of the debentures 
liquidity and capital resources cash used in operating activities totaled  in as compared to  in the increase in is principally related to increased research and development expenses after adjusting for non cash items 
cash used in investing activities totaled  in as compared to  in the difference in investing activities principally reflects the purchase of short term investments with the proceeds from the private placements  described below  completed by the company in and  net of the sales of short term investments which were subsequently used to fund operations 
cash flows from financing activities totaled  in as compared to  in the difference in financing activities principally reflects the effect of the private placements  described below  completed by the company in and since its inception  the company has primarily satisfied its working capital requirements from the sale of the company s securities through private placements 
these private placements have included the sale of preferred stock and common stock  as well as notes payable and convertible debentures 
each private placement has included the issuance of warrants to purchase common stock 
a summary of financings completed during the three years ended december  is as follows net proceeds date raised securities issued june million common stock september million convertible debentures february million common stock february million preferred stock in the future  the company s working capital and capital requirements will depend on numerous factors  including the progress of the company s research and development activities  the level of resources that the company devotes to the developmental  clinical  and regulatory aspects of its products  and the extent to which the company enters into collaborative relationships with pharmaceutical and biotechnology companies 
at december   the company had available cash  cash equivalents  and investments of approximately million and working capital of approximately million 
the company believes that the level of financial resources available at december  will provide sufficient working capital to meet its anticipated expenditures for more than the next twelve months 
the company may raise additional capital in the future through collaboration agreements with other pharmaceutical or biotechnology companies  debt financing and equity offerings 
there can be no assurance  however  that the company will be successful or that additional funds will be available on acceptable terms  if at all 
recent accounting pronouncements in june  the financial accounting standards board fasb issued statement of financial accounting standards no 
 accounting for derivative instruments and hedging activities sfas  which was amended by sfas no 
and sfas no 
and is effective for all fiscal quarters of fiscal years beginning after june  the statement requires that all derivative investments be recorded in the balance sheet at fair value 
changes in the fair value of derivatives are recorded each period in current earnings or comprehensive income depending on whether a derivative is designated as part of a hedge transaction  and the type of hedge transaction 
the company does not expect the adoption of the statement to have a material effect on its financial statements 
in october  the company adopted staff accounting bulletin no 
 revenue recognition in financial statements sab 
sab clarifies the sec s views related to revenue recognition and disclosure 
the adoption of sab did not effect the company s financial position or results of operations 
item a 
quantitative and qualitative disclosures about market risk we currently own financial instruments that are sensitive to market risks as part of our investment portfolio 
our investment portfolio is used to preserve our capital until it is required to fund operations  including our research and development activities 
none of these market risk sensitive instruments are leveraged or held for trading purposes 
our investment portfolio consists of united states agency bonds and corporate debt obligations 
these investments are subject to interest rate risk  and could decline in value if interest rates fluctuate 
due to the conservative nature of these instruments  we do not believe that we have a material exposure to interest rate risk 

